Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Kaken Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	63,059	50,625	59,561	61,025	63,706	59,722
Short-Term Investments	16,694	14,699	14,699	13,599	13,599	13,599
Cash & Short-Term Investments	79,753	65,324	74,260	74,624	77,305	73,321
Cash Growth	20.56%	-12.03%	-0.49%	-3.47%	5.43%	25.22%
Receivables	29,879	23,744	19,268	20,260	20,549	21,800
Inventory	17,549	17,167	15,563	14,980	15,197	12,274
Other Current Assets	898	739	812	749	611	941
Total Current Assets	128,079	106,974	109,903	110,613	113,662	108,336
Property, Plant & Equipment	26,394	25,355	25,498	25,734	25,020	25,518
Long-Term Investments	20,286	29,241	20,312	18,871	22,447	20,376
Other Intangible Assets	7,443	7,462	6,741	8,236	625	414
Long-Term Deferred Tax Assets	-	2,590	3,873	1,725	1,577	3,229
Other Long-Term Assets	11,220	1	1	2	1	2
Total Assets	193,422	171,623	166,328	165,181	163,332	157,875
Accounts Payable	9,159	7,099	6,219	5,939	8,569	8,682
Accrued Expenses	444	1,639	1,561	1,394	1,450	1,710
Short-Term Debt	3,850	3,850	3,850	3,850	3,850	3,850
Current Income Taxes Payable	6,199	4,222	7,828	5,979	5,294	5,707
Other Current Liabilities	9,563	2,214	1,380	1,887	2,113	1,706
Total Current Liabilities	29,215	19,024	20,838	19,049	21,276	21,655
Long-Term Deferred Tax Liabilities	1,947	1,947	1,771	2,229	-	-
Other Long-Term Liabilities	819	505	535	540	423	449
Total Liabilities	38,165	27,869	29,493	26,857	27,075	29,407
Common Stock	23,853	23,853	23,853	23,853	23,853	23,853
Additional Paid-In Capital	11,500	11,462	11,406	11,406	11,406	11,406
Retained Earnings	140,472	128,506	126,135	126,347	122,462	114,869
Treasury Stock	-28,630	-28,613	-30,026	-28,714	-26,304	-23,373
Comprehensive Income & Other	8,062	8,546	4,889	4,854	4,840	1,713
Total Common Equity	155,257	143,754	136,257	137,746	136,257	128,468
Minority Interest	-	-	578	578	-	-
Shareholders' Equity	155,257	143,754	136,835	138,324	136,257	128,468
Total Liabilities & Equity	193,422	171,623	166,328	165,181	163,332	157,875
Total Debt	3,850	3,850	3,850	3,850	3,850	3,850
Net Cash (Debt)	75,903	61,474	70,410	70,774	73,455	69,471
Net Cash Growth	21.83%	-12.69%	-0.51%	-3.65%	5.73%	27.05%
Net Cash Per Share	2004.24	1629.01	1874.05	1863.55	1903.47	1774.94
Filing Date Shares Outstanding	37.87	37.87	37.47	37.79	38.32	38.92
Total Common Shares Outstanding	37.87	37.87	37.47	37.82	38.32	38.92
Working Capital	98,864	87,950	89,065	91,564	92,386	86,681
Book Value Per Share	4099.33	3796.01	3636.14	3642.30	3555.92	3301.06
Tangible Book Value	147,814	136,292	129,516	129,510	135,632	128,054
Tangible Book Value Per Share	3902.80	3598.97	3456.25	3424.53	3539.61	3290.43

Source: S&P Capital IQ. Standard template. Financial Sources.